Abstract:
A method of classifying a lung graft subjected to normothermic ex vivo lung perfusion (EVLP), during perfusion and/or after perfusion, the method comprising: a) collecting a test sample from the lung graft; b) measuring a polypeptide level of a negative transplant predictor gene product selected from CCG predictor gene products M-CSF, IL-8 SCGF-beta, GRO-alpha, G-CSF, MIP-1 alpha, and/or MIP-1beta, endothelin predictor gene products endothelin 1 (ET-1) and/or big ET-1, and/or apoptosis predictor gene products cytokeratin 18 (CK-18), caspase 3 and/or HMGB-1 in the sample and/or determining a metabolite profile of the sample for lung grafts that are from donors where the death was due to cardiac death (DCD); c) identifying the graft as a good candidate for transplant or a poor candidate for transplant wherein an increased polypeptide level of one or more negative transplant outcome predictor gene products compared to an outcome control or a reference metabolic profile is indicative the graft is a poor candidate for transplant.
Abstract:
The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.
Abstract:
The present invention is further directed to methods and compositions for identifying target nucleic acids that are involved in cancer metastasis.
Abstract:
The present invention is directed to methods and compositions for modulating proteins involved in the immune response. The present invention further provides methods and compositions for treatment of autoimmune disease and cancer by modulating the expression and activity of such proteins.
Abstract:
The present invention is further directed to methods and compositions for modulating the activity of the Toso protein. The invention further encompasses treatment of disorders associated with inflammation, autoimmune disorders, and cancer using compositions that include a soluble Toso protein.
Abstract:
A functional electrical stimulation (FES) device and system. In one embodiment, sequential bipolar pulse stimulation may be provided to an area of a living body via one or more electrode leads applied to the area via a FES device comprising a current pulse generating circuit comprising output nodes for operative coupling to the one or more electrode leads, and configured for operative coupling to a voltage supply. The current pulse generating circuit generally comprises positive and negative stimulation paths drawing from the voltage supply to respectively apply positive and negative currents through the area via the one or more electrode leads. In one example, the stimulation paths comprise respective capacitive elements, a capacitance ratio of which dictating, at least in part, an amplitude ratio of the positive and negative currents, wherein periodic alternative activation of the stimulation paths provides the sequential bipolar pulse stimulation.
Abstract:
A system for rehabilitating patients affected by balance disorders with or without vestibular hypofunction and/or malfunction with or without an associated hearing loss, which includes sensors of sound and head movement, processing circuitry, a power source coupled to head phones, an air conduction hearing aid, bone conduction hearing aid, middle ear implant or an electrical stimulator implanted into the cochlea capable of stimulating areas within the cochlea with the potential for current spread to surrounding non-auditory areas including the vestibular system.
Abstract:
This document involves methods and materials related to inhibiting cyclin D polypeptide activity. For example, this document provides methods and materials that can be used to (1) identify mammals or cells in need of cyclin D polypeptide inhibition and (2) administer an agent capable of inhibiting cyclin D polypeptide activity.
Abstract:
There is provided herein vesicles comprising a bilayer comprising porphyrin-phospholipid conjugate, wherein the porphyrin-phospholipid conjugate comprises one porphyrin, porphyrin derivative or porphyrin analog covalently attached to a lipid side chain, preferably at the sn-1 or the sn-2 position, of one phospholipids, wherein the vesicle is 1-100 microns in diameter.
Abstract:
A method and apparatus for providing functional electrical stimulation to an individual for altering a mood or emotional parameter associated with a mood or emotional state is provided. The method involves providing functional electrical stimulation to facial muscles of the individual so as to elicit a detectable contraction in said muscles associated with a facial expression associated with a desired mood or emotional parameter.